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an additional cost of €1479. The incremental CE was
€5154/LYG (95% conﬁdence interval (CI) €3833/LYG-
€9944/LYG). Sensitivity analyses on effectiveness, cost of
complications and discounting shows the robustness 
of the results. A 2nd order Monte Carlo analysis based
on the 95% CI obtained in the GISSI study showed that
in 99.1% of patients n-3 PUFAs is a cost-effective treat-
ment option if €20,000/LYG is taken as a threshold.
CONCLUSIONS: Adding n-3 PUFAs to standard treat-
ment in the secondary prevention after MI appears cost-
effective in Belgium.
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OBJECTIVES: The cost-effectiveness of hypolipemiant
treatment with lovastatin (HMG-CoA reductase
inhibitor, 20, 40 and 80mg/day), cholestyramine (bile
acid sequestrant, 12 and 24g/day) gemﬁbrozil (ﬁbrate,
1,2g/day) in individuals with hypercholesterolemia 
>200mg/day was assessed in this study. METHODS:
Cost-effectiveness was measured in terms of met cost per
life year gained (LYG) comparing costs and beneﬁts in
Spain. The net treatment cost was deﬁned as the total cost
including medication, control measures and treatment of
adverse side effects less savings from coronary heart
disease costs. Effectiveness was measured using the Fram-
ingham equation, the information about the prevalence
of cardiovascular risk factors, and life expectancy accord-
ing to age and sex in Catalonia. Cost and beneﬁts were
discounted using a 5% discount rate. RESULTS: The
ranking list of efﬁciency in both men and women and for
different pre-treatment cholesterol levels was: lovastatin
20mg/day, cholestyramine 12g/day, lovastatin 40mg/day,
gemﬁbrozil 1.2g/day, cholestyramine 24g/day, and lovas-
tatin 80mg/day. Cost-effectiveness in terms of cost per
LGY ranged from $15,487 to 289,116 in men and from
$52,403 to 604,809 in women, according to age, sex, and
cholesterol concentration. In individuals with a choles-
terol concentration of 300mg/dl cost-effectiveness ranged
from $33,850 to 142,910 per LYG in men and from
$104,100 to 350,660 per LYG in women. The highest
cost-effectiveness was obtained in men aged 40–44 years
with 380mg/dl of cholesterol and in women aged 50–54
years with 380mg/dl of cholesterol, while the lowest cost-
effectiveness was observed in both men and women aged
70–75 years with 200mg/dl of cholesterol. Incremental
cost-effectiveness analysis showed that treating individu-
als with hypercholesterolemia using lovastatin was more
cost-effective than using cholestyramine and gemﬁbrozil.
CONCLUSION: This study has shown that lovastatin, an
HMG Co-A reductase inhibitor, was the most cost-
effective hypolipemiant drug assessed in this study.
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OBJECTIVES: To evaluate the effectiveness in the modi-
ﬁcation of cardiovascular risk (CVR) according to WHO-
ISH guidelines of an educative personalized interven-
tion in hypertensive (HT) patients in primary care.
METHODS: Observational, prospective and controlled
study. Two hundred seventy-nine general practitioners
(GP) were recruited throughout Spain. HT patients were
followed for six months. Investigators were cluster-ran-
domized to Control group (CG) and Intervention group
(IG). The CG investigators did usual clinical practice,
whereas IG investigators did usual clinical practice plus a
personalized educative intervention, which consisted in
the ad hoc printing by using a speciﬁc software of educa-
tive leaﬂets oriented to the modiﬁcation of life habits and
to control of cardiovascular risk factors for each patient.
RESULTS: HT patients totaling 4,019 were evaluated.
Both groups were comparative at baseline with respect to
sociodemographic variables and CVR distribution. The
IG showed a statistically signiﬁcant and clinically relevant
improvement in hypertension control (54.1% of con-
trolled hypertension in IG vs. 48.0% in CG; p < 0.01).
The ﬁnal CVR distribution was signiﬁcantly better in the
IG than in the CG. The IG patients improved signiﬁcantly
their knowledge of hypertension disease (from 36.8% to
80.6% of good knowledge in IG vs from 32.5% to 70.0%
in CG; p < 0.001). There were no differences in the evo-
lution of smoking, cholesterol and obesity. The overall
satisfaction with medical care was higher in the IG. Of
the patients, 90.9% answered “Always” to the question
“When you talk to your physician, does he/she answer
clearly to your questions?” vs 51.5% of patients in CG
(p < 0.05). CONCLUSION: The proposed procedure for
the personalized educative activity with the hypertensive
patient has proven to be feasible and useful for hyper-
tension and CVR control in general practitioners. The
intervention seems to improve knowledge about hyper-
tension and satisfaction level with medical care.
